ANNX

Rating neutralAI Memo

Annexon

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ANX1502 proof-of-concept update • 2026-11-30

Base target: $4 / p=45% prob

Biggest risk

ARCHER II efficacy remains unproven in Phase 3, the additional month-24 endpoint may prolong the investment decision, and BLA filing does not imply approval. Q2 R&D expense rose to $46.6 million as registrational work continued [#SEC-8K-2026-08-12].

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Three program-specific milestones before year-end could validate Annexon's C1-focused pipeline. The company reported $209.2 million of cash and short-term investments at June 30 and, including access to its credit facility, projected runway into 2028 [#SEC-8K-2026-08-12].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-25

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ARCHER II month-24 assessment
Three program-specific milestones before year-end could validate Annexon's C1-focused pipeline.
The company reported $209.2 million of cash and short-term investments at June 30 and, including access to its credit facility, projected runway into 2028 [#SEC-8K-2026-08-12].

BearKey bullets

A negative or ambiguous ARCHER II month-15 readout could sharply impair the largest near-term asset thesis.
ANX1502 remains proof-of-concept-stage, so biomarker findings may not establish clinical benefit.
Tanruprubart faces regulatory submission, review and eventual commercialization risk despite the European application already being under review.

WatchKey bullets

ANX1502 proof-of-concept update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=45%)

Target spread vs base: +71% / -61%

Scenario probabilities

Bull Target: $7 (p=25%)Base Target: $4 (p=45%)Bear Target: $2 (p=30%)

Commentary

Primary-source milestone detail is strong, but independent coverage and quantified sentiment inputs are thin; the zero sentiment fields denote unavailable measurements, not neutral readings. The August Q2 release reported a $0.28 loss per share, versus a $0.24 consensus loss cited by secondary coverage, with shares down about 6% in early premarket trading; that initial reaction does not establish a lasting post-print trend (company release, Investing.com). The May director open-market purchase is an alignment signal, not evidence of clinical success [#SEC-FORM4-2026-05-29].

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ARCHER II month-24 assessment

Scenarios

Bull Target (Scenario probability)

$7 / p=25% prob

Base Target (Scenario probability)

$4 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
ANX1502 proof-of-concept update
A fall 2026 update from the oral C1-inhibitor study in cold agglutinin disease should address pharmacology and hemolysis markers. This earlier-stage signal could broaden platform value but should carry less weight than the registrational programs [#SEC-8K-2026-08-12].
Prob 55.00% • Move 20.00% • Priced-in 20.00%
EVENT2026-12-31
ARCHER II month-15 geographic-atrophy results
Annexon expects the vonaprument Phase 3 month-15 primary-endpoint readout in Q4 2026. A convincing vision-preservation result could materially revalue the company; failure is the principal downside risk. The added month-24 endpoint provides another assessment, not assurance of success [#8-K-2026-08-12] [#SEC-8K-2026-08-12].
Prob 50.00% • Move 55.00% • Priced-in 30.00%
EVENT2026-12-31
Tanruprubart U.S. BLA submission
Annexon expects to submit a BLA for Guillain-Barré syndrome in Q4 2026 using U.S. and European FORWARD data. The European marketing application is under review; submission, acceptance and approval remain separate hurdles [#SEC-8K-2026-08-12].
Prob 65.00% • Move 20.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ARCHER II month-24 assessment
2027-09-30
Annexon expects final ARCHER II completion, including the independent month-24 primary endpoint, in Q3 2027. It offers a later efficacy test but extends uncertainty if month-15 evidence is inconclusive [#SEC-8K-2026-08-12].
Prob 50% • Move 35% • Priced-in 15%

Risks

A negative or ambiguous ARCHER II month-15 readout could sharply impair the largest near-term asset thesis.
ANX1502 remains proof-of-concept-stage, so biomarker findings may not establish clinical benefit.
Tanruprubart faces regulatory submission, review and eventual commercialization risk despite the European application already being under review.
The $200 million credit facility is not equivalent to cash on hand; borrowing terms and continuing trial spending matter to dilution and runway [#SEC-8K-2026-08-12].

Peers

Symbol	Summary
NVCT	Similarly sized development-stage biotech illustrating clinical-event and financing sensitivity, but its oncology focus is not a mechanism or indication match.
PHAR	Rare-disease biopharma comparator, but its commercial profile and indications differ; not a direct valuation multiple for Annexon's clinical assets.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25

Loading AI feed…

Symbol

Summary

NVCT

Similarly sized development-stage biotech illustrating clinical-event and financing sensitivity, but its oncology focus is not a mechanism or indication match.

PHAR

Rare-disease biopharma comparator, but its commercial profile and indications differ; not a direct valuation multiple for Annexon's clinical assets.